Oncolytics Biotech Inc T.ONC

Mouse Study

[lonc17]

Pre-clinical but very relevant to Goblet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1018767/full


Herein we report for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. Our data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the expression of PD-L1 marker on respective target cells. The combinatorial treatment has successfully immune populated the MSS tumor TME in all three study models. Immunotherapy, which has achieved phenomenal success in many cancer types, may now be successfully implemented in MSS ‘cold’ or immunosuppressive CRC tumors, and provides a rationale to extend combination reovirus-ICI therapy into clinical testing.

[westcoast1000]

Thanks to Ionc17. This is an extremely interesting and methodologically sound article just pulbished a few days ago, although the work was largely done a few years back.  I suggest reading at least the abstract carefully. It is enthusiastic about turning immune-insensitive cells into immotheraphy-sensitve cells. Cold tumors to hot. Very important, IMHO. 

[Noteable]

One of the significant findings of this MSS CRC study which was just published on October 25, 2022 is: Reovirus and anti-PD-1 combination therapy synergistically enhances the anti-tumor adaptive immune response in CT26 mouse tumors which proved the authors  hypothesis that a combination of reovirus with an ICI, such as an anti-PD-1, would have synergistic therapeutic efficacy against

[Noteable]

Should read: "...revolutionary finding .."

[Buckhenry]

you have reached new lows here notable......

[westcoast1000]

Note also that while the tumors were induced in mice, the cell lines for nearly all the tumor cells came from human CRC patients. At least that is how I read it.  From the text of the article: "Fifty-nine human- and two mouse-origin CRC cell lines"

[westcoast1000]

Finally, these "Frontiers" journals are very prestigious and well cited.  Frontiers in Oncology is the third most cited journal in its field and has an impact factor of 6.24. If the FDA accepts this article as evidence of the mechanism for changing the tumor environment and making CRC amenable to checkpoint inhibitors, then this is a very important study. 

[Buckhenry]

will this make the offer go from 8 to 16 billion..... I need to know so I can upgrade to a 747-8 instead of the 747-4. size matters on 747's

[Noteable]

Presented today .... https://www.researchgate.net/publication/364746757_Potentiating_effect_of_reovirus_on_immune_checkpoint_inhibition_in_microsatellite_stable_colorectal_cancer Therein the authors reported for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus

[westcoast1000]

Amen, Noteable.  Let us hope big pharma these publications and proceeds with investments in ONCY. Let us hope the FDA encourages these investments with fast track and accelerated approvals. Let us hope these important milestones happen soon. 

[askretka]

Excellent! We'll know in a few days with Abstract release and KOL. There have been a lot of new articles this year on significance of RAS pathway or KRAS and we know Pelareorep works well there. Cheers!!!

[fox7mf]

A great thread of conversation all, and thanks for the info concerning this newly published article. I don't know if Onc has ever had such a long & uninterrupted string of extremely positive news on every front & with every trial. Those involved in the upcoming pancreatic cancer presentations seem to be chomping at the bit for the date to arrive. It's hard to imagine this not